14. The relationship between BRAF V600E immunohistochemistry and characteristics of well-differentiated thyroid carcinoma in the pediatric population
Main Article Content
Abstract
Thyroid cancer is rare in children and mainly seen in well-differentiated thyroid carcinoma. The BRAF V600E mutation is among the most studied gene mutations, especially in adults. However, in children, the mutation rate and the association of BRAF V600E mutation status with pathological features and disease prognosis remain unclear. Among 99 patients, 18 were positive when immunohistochemistry revealed mutations in the BRAF V600E gene, accounting for 18.2%. No relationship was found between the expression of the BRAF V600E mutation and the clinical and subclinical features of thyroid cancer in children, such as age, sex, bilateral cancer lesions, multifocal cancer, extra thyroidal extension, lymph node metastasis, distant metastasis, and pathological results.
Article Details
Keywords
thyroid cancer, pediatric cancer, BRAF V600E
References
2. Z Al-Qurayshi, A Hauch, S Srivastav, et al. A National Perspective of the Risk, Presentation, and Outcomes of Pediatric Thyroid Cancer. JAMA Otolaryngol Head Neck Surg. 2016;142(5):472-478.
3. J Kim, Z Sun, MA Adam, et al. Predictors of nodal metastasis in pediatric differentiated thyroid cancer. J Pediatr Surg. 2017;52(1):120-123.
4. G Acquaviva, M Visani, A Repaci, et al. Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance. Histopathology. 2018;72(1):6-31.
5. D Chakraborty, S Shakya, S Ballal, et al. BRAF V600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation. J Pediatr Endocrinol Metab. 2020;33(11):1465-1474.
6. J Zhao, P Liu, Y Yu, et al. Comparison of diagnostic methods for the detection of a BRAF mutation in papillary thyroid cancer. Oncol Lett. 2019;17(5):4661-4666.
7. DJ Givens, LO Buchmann, AM Agarwal, et al. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma. Laryngoscope. 2014;124(9):E389-393.
8. G Sassolas, Z Hafdi-Nejjari, A Ferraro, et al. Oncogenic alterations in papillarythyroid cancers of young patients. Thyroid. 2012;22(1):17-26.
9. E Rosenbaum, G Hosler, M Zahurak, et al. Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma. Mod Pathol. 2005;18(7):898-902.
10. N Oishi, T Kondo, T Nakazawa, et al. Frequent BRAF (V600E) and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan. Endocr Pathol. 2017;28(2):103-111.
11. AS Alzahrani, AK Murugan, E Qasem, et al. Single Point Mutations in Pediatric Differentiated Thyroid Cancer. Thyroid. 2017;27(2):189-196.
12. LE Henke, SM Perkins, JD Pfeifer, et al. BRAF V600E mutational status in pediatric thyroid cancer. Pediatr Blood Cancer. 2014;61(7):1168-1172.
13. S Poyrazoglu, R Bundak, F Bas, et al. Clinicopathological Characteristics of Papillary Thyroid Cancer in Children with Emphasis on Pubertal Status and Association with BRAF(V600E) Mutation. J Clin Res Pediatr Endocrinol. 2017;9(3):185-193.